mHealth to help pregnant and postpartum women in recovery for opioid use disorder

移动医疗帮助孕妇和产后妇女恢复阿片类药物使用障碍

基本信息

批准号：
10449316
负责人：
Patricia A Cavazos-Rehg
金额：
$ 23.63万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10449316
关键词：
Adult African American Area Attitude Behavior Caring Characteristics Clinic Clinical Control Groups Data Drug Prescriptions Education Effectiveness Feedback Focus Groups Grant Health Technology High Risk Woman Hospitals Individual Infant Care International Intervention Interview Intuition Life Measures Methods Missouri Names Opioid Outcome Participant Perinatal Persons Physicians Postpartum Women Poverty Pregnancy Pregnant Women Prevalence Provider Public Health Randomized Randomized Controlled Trials Recovery Reporting Research Project Grants Signal Transduction Site Standardization Suggestion Testing Time United States Substance Abuse and Mental Health Services Administration Universities Visit Vulnerable Populations Washington Woman Work acceptability and feasibility base clinical care design digital treatment empowerment ethnic minority population feasibility testing follow up assessment follower of religion Jewish high risk high school improved mHealth medical schools medication-assisted treatment mobile application new technology opioid abuse opioid epidemic opioid mortality opioid use disorder racial and ethnic recruit response satisfaction sobriety standard of care theories tool treatment adherence treatment as usual treatment planning treatment risk trend usability

项目摘要

The opioid epidemic has resulted in widespread detrimental consequences among vulnerable populations in Missouri, especially among pregnant and postpartum women (PPW) with opioid use disorder (OUD). Perinatal use of medication-assisted treatment (MAT) within a comprehensive treatment plan is the current standard of care, however PPW struggling with OUD may underestimate or misjudge its benefits. At the same time, emerging findings signal that mobile health (mHealth) technologies have the potential to support healthier behaviors among individuals with OUD. In this project, we will test the utility of a theoretically-based digital therapeutics tool (uMAT-R) to encourage MAT adherence and treatment retention while considering the unique needs of PPW. In Aim #1, we will conduct four focus groups with PPW with OUD (target users) on the intervention components of uMAT-R, gathering feedback on theory-driven components that are candidates for inclusion in the tool and eliciting suggestions for additional intervention components. In Aim #2, the tool will be beta-tested for technical/navigational issues among 20 participants. In Aim #3, we will conduct a pilot randomized controlled trial (RCT) among adult PPW with OUD (n=60). This RCT is designed to test the feasibility, acceptability, and preliminary efficacy of uMAT-R (n=40) versus a control group (n=20 who receive treatment-as-usual) regarding participants’ treatment adherence, sobriety, and improved MAT attitudes, norms, and perceived control. Recruitment for all Aims will occur at a clinic in St. Louis, Missouri that provides perinatal medication-assisted treatment (MAT) and high-risk maternity care to PPW struggling with OUD. Clinically meaningful effect size and attrition estimates will aid in the planning of a larger RCT in which we will test uMAT-R on a larger scale and expand our recruitment to other clinics across Missouri and other states. This novel technology could be an invaluable tool to assist physicians in the treatment of OUD among PPW.

阿片类药物的流行对弱势群体造成了广泛的后果密苏里州人口，尤其是使用阿片类药物的孕妇和产后妇女 (PPW) 使用障碍（OUD）。围产期使用药物辅助治疗（MAT）。综合治疗计划是当前的护理标准，但 PPW 却面临着困难 OUD 可能会低估或误判其好处，同时，新出现的调查结果表明。移动医疗（mHealth）技术有潜力支持更健康的行为在这个项目中，我们将测试基于理论的实用性。数字治疗工具 (uMAT-R)，以鼓励 MAT 依从性和治疗保留，同时考虑到 PPW 的独特需求，在目标 1 中，我们将与 PPW 开展四个焦点小组活动。与 OUD（目标用户）就 uMAT-R 的干预部分进行合作，收集关于理论驱动的组件是包含在工具中并征求建议的候选组件在目标 #2 中，该工具将进行 beta 测试。在目标 3 中，我们将在 20 名参与者中讨论技术/导航问题。在患有 OUD 的成人 PPW 中进行的随机对照试验 (RCT)（n=60）。测试 uMAT-R (n=40) 与对照的可行性、可接受性和初步功效组（n=20 接受常规治疗的人）关于参与者的治疗依从性，清醒，并改善 MAT 态度、规范和感知控制。将在密苏里州圣路易斯的一家提供围产期药物辅助治疗的诊所进行 (MAT) 和高危产妇护理对与 OUD 作斗争的 PPW 具有临床意义的影响。规模和损耗估计将有助于规划更大的 RCT，我们将在其中测试 uMAT-R 更大规模，并将我们的招募范围扩大到密苏里州和其他州的其他诊所。这项新技术可能成为协助医生治疗 OUD 的宝贵工具 PPW 之中。